Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-Specific Dosing of Voriconazole
NCT03731169Phase 4Completed
- Sponsor
- University Health Network
- Start
- Jan 2018
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of voriconazole in invasive aspergillosis (IA) (2 arms), sponsored by University Health Network. Primary endpoints: Voriconazole trough concentrations at steady-state at 1 year, Number of dose adjustments needed to achieve therapeutic voriconazole levels at 1 year and 1 more. Started Jan 2018; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03731169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731169.